IL158761A0 - Novel treatment for obsessive-compulsive disorders (ocd) and ocd-related disorders using gvg - Google Patents

Novel treatment for obsessive-compulsive disorders (ocd) and ocd-related disorders using gvg

Info

Publication number
IL158761A0
IL158761A0 IL15876102A IL15876102A IL158761A0 IL 158761 A0 IL158761 A0 IL 158761A0 IL 15876102 A IL15876102 A IL 15876102A IL 15876102 A IL15876102 A IL 15876102A IL 158761 A0 IL158761 A0 IL 158761A0
Authority
IL
Israel
Prior art keywords
ocd
disorders
gvg
obsessive
novel treatment
Prior art date
Application number
IL15876102A
Other languages
English (en)
Original Assignee
Brookhaven Science Ass Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brookhaven Science Ass Llc filed Critical Brookhaven Science Ass Llc
Publication of IL158761A0 publication Critical patent/IL158761A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15876102A 2001-05-14 2002-05-08 Novel treatment for obsessive-compulsive disorders (ocd) and ocd-related disorders using gvg IL158761A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/853,392 US6462084B1 (en) 2001-05-14 2001-05-14 Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
PCT/US2002/014344 WO2002092071A1 (fr) 2001-05-14 2002-05-08 Nouveau traitement d'un trouble obsessionnel-compulsif (ocd) et de troubles associes aux ocd faisant appel au gvg

Publications (1)

Publication Number Publication Date
IL158761A0 true IL158761A0 (en) 2004-05-12

Family

ID=25315916

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15876102A IL158761A0 (en) 2001-05-14 2002-05-08 Novel treatment for obsessive-compulsive disorders (ocd) and ocd-related disorders using gvg

Country Status (18)

Country Link
US (2) US6462084B1 (fr)
EP (1) EP1392273A4 (fr)
JP (1) JP2004533445A (fr)
KR (1) KR20040028758A (fr)
CN (1) CN1509168A (fr)
BR (1) BR0209614A (fr)
CA (1) CA2446641A1 (fr)
CZ (1) CZ20033379A3 (fr)
HR (1) HRP20030894A2 (fr)
HU (1) HUP0400032A3 (fr)
IL (1) IL158761A0 (fr)
MX (1) MXPA03010406A (fr)
NO (1) NO20035037L (fr)
NZ (1) NZ529613A (fr)
PL (1) PL367362A1 (fr)
TW (1) TWI313599B (fr)
WO (1) WO2002092071A1 (fr)
YU (1) YU89103A (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002043731A2 (fr) 2000-11-30 2002-06-06 University Of Florida Traitements de troubles neurogenetiques, de troubles du controle des impulsions, et cicatrisation des lesions
CA2488566A1 (fr) * 2002-06-27 2004-01-08 Warner-Lambert Company Llc Methode de traitement du trouble d'hyperactivite avec deficit de l'attention
EP1617862B1 (fr) * 2003-04-25 2012-12-05 Allergan, Inc. Neurotoxine botulique pour le traitment des symptomes de comportements compulsifs obsedants
US7393537B2 (en) 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US20110275664A1 (en) * 2005-09-26 2011-11-10 The Regents Of The University Of Colorado,A Body Corporate Method for treating drug and behavioral addictions
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8969413B2 (en) * 2010-02-25 2015-03-03 Catalyst Pharmaceutical Partners Methods of using (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2014197744A1 (fr) * 2013-06-05 2014-12-11 Synchroneuron, Inc. Formulations d'acamprosate, procédés d'utilisation de celles-ci, et combinaisons comprenant celles-ci
CN104306736A (zh) * 2014-10-31 2015-01-28 哈尔滨市海江科技开发有限公司 一种治疗疑病症的膏药及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761429A (en) 1985-07-22 1988-08-02 Kenneth Blum Enkephalinase and endorphinase inhibitors as anti-craving compositions
US5189064A (en) 1985-07-22 1993-02-23 Matrix Technologies, Inc. Treatment of ***e addiction
US4786647A (en) 1986-06-30 1988-11-22 University Of Florida Method for eliciting anxiolysis
US4980168A (en) 1989-10-13 1990-12-25 Natrol, Inc. Dietary supplement for children
EP0767174A1 (fr) 1991-11-21 1997-04-09 Ciba-Geigy Ag Nouveaux acides aminalcanephosphiniques et leurs sels
HU222339B1 (hu) * 1992-05-20 2003-06-28 Northwestern University S-(+)-4-amino-3-(2-metil-propil)-butánsav, és gyógyászati szempontból elfogadható sói, ezeket tartalmazó gyógyászati készítmények, valamint az (S)-(+)-4-amino-3-(2-metil-propil)-butánsav előállítása
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US6071537A (en) 1996-06-28 2000-06-06 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating obesity
US5776956A (en) 1996-07-30 1998-07-07 Lectec Corporation Use of cotinine in treating psychiatric disorders
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
EP1043980A2 (fr) 1997-10-28 2000-10-18 Schering Corporation Procede de reduction de l'appetence chez les mammiferes
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
WO2000023059A2 (fr) * 1998-10-20 2000-04-27 Ortho-Mcneil Pharmaceutical, Inc. Derives anticonvulsifs utiles dans les traitements de dependance, d'accoutumance et d'abus d'alcool
CN1196482C (zh) 1999-02-01 2005-04-13 奥索-麦克尼尔药品公司 抗惊厥药衍生物在治疗神经性食欲过盛症中的应用
CZ20013061A3 (cs) 1999-02-24 2002-06-12 University Of Cincinnati Pouľití sulfamátových derivátů pro léčbu poruch kontroly impulsů
JP2003530300A (ja) 1999-04-08 2003-10-14 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 体重低下を維持することに有用な抗痙攣薬誘導体
WO2002043731A2 (fr) * 2000-11-30 2002-06-06 University Of Florida Traitements de troubles neurogenetiques, de troubles du controle des impulsions, et cicatrisation des lesions

Also Published As

Publication number Publication date
CN1509168A (zh) 2004-06-30
US20020169103A1 (en) 2002-11-14
HRP20030894A2 (en) 2004-06-30
CA2446641A1 (fr) 2002-11-21
US6462084B1 (en) 2002-10-08
PL367362A1 (en) 2005-02-21
HUP0400032A2 (hu) 2004-04-28
HUP0400032A3 (en) 2012-09-28
JP2004533445A (ja) 2004-11-04
YU89103A (sh) 2006-08-17
KR20040028758A (ko) 2004-04-03
MXPA03010406A (es) 2004-05-05
WO2002092071A1 (fr) 2002-11-21
NO20035037L (no) 2004-01-07
EP1392273A1 (fr) 2004-03-03
NZ529613A (en) 2006-09-29
EP1392273A4 (fr) 2004-11-24
NO20035037D0 (no) 2003-11-13
TWI313599B (en) 2009-08-21
CZ20033379A3 (cs) 2004-12-15
BR0209614A (pt) 2004-12-07

Similar Documents

Publication Publication Date Title
GB0112343D0 (en) Well treatment
AU2002358934A1 (en) Pelvic disorder treatment device
GB0129976D0 (en) Treatment method
IL158761A0 (en) Novel treatment for obsessive-compulsive disorders (ocd) and ocd-related disorders using gvg
EP1422743A4 (fr) Systeme de traitement
AU2002236781A1 (en) Treatment for snoring
GB0120147D0 (en) Treatment method
GB0319239D0 (en) Process and apparatus
GB0105899D0 (en) Fibrosis reduction treatment
GB0127384D0 (en) Well treatment system
GB0130763D0 (en) Treatment methods
GB0103031D0 (en) Novel treatment
GB2376239B (en) Cask treatment
GB0126253D0 (en) Treatment method
AU2002101010A4 (en) Treatment process and apparatus
HK1049477A1 (en) Apparatus for beauty treatment.
GB0130694D0 (en) Treatment
GB2413797B (en) Microorganisms for well treatment
GB0110191D0 (en) Sterilization method
GB0102927D0 (en) Treatment method
AU2002229796A1 (en) Method for treating sleep disorders
GB0116837D0 (en) Treatment
GB0109519D0 (en) Nimico treatment
GB0117425D0 (en) Novel treatment
GB0117419D0 (en) Novel treatment